MassBio regularly spotlights a member company and its efforts in advancing the life sciences industry and supporting the patients we serve. This summer, we profile Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine disease. We speak with Dr. David Meeker, Chairman, President, and Chief Executive Officer of Rhythm. David previously served as President and CEO of KSQ Therapeutics, and worked at Sanofi Genzyme, where he led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases. David is also an active and committed member of the MassBio Board of Directors.

See all MassBio News